^
Association details:
| Biomarker: | EGFR L858R + ALK rearrangement |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Concurrent EGFR mutation and ALK rearrangement in stage IV lung adenocarcinoma-a case report and a literature review
Published date:
02/11/2021
Excerpt:
We describe a case of a woman with stage IV lung adenocarcinoma with 2 synchronous mutations at diagnosis, the EGFR p.(Leu858Arg) mutation, and an ALK rearrangement….She started treatment with gefitinib 250 mg in February/2019. After 16 months, she maintains gefitinib with stable disease...
DOI:
10.1097/j.pbj.0000000000000124
